Collegium Pharmaceutical
COLL
83 hedge funds and large institutions have $235M invested in Collegium Pharmaceutical in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 12 closing their positions.
97% more call options, than puts
Call options by funds: $526K | Put options by funds: $267K
80% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 20
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2.16% less ownership
Funds ownership: 81.46% → 79.3% (-2.2%)
6% less funds holding
Funds holding: 88 → 83 (-5)
35% less capital invested
Capital invested by funds: $363M → $235M (-$128M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$22M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$12M |
| 3 |
Morgan Stanley
New York
|
+$11.5M |
| 4 |
CCM
Cadian Capital Management
New York
|
+$6.52M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$6.44M |
Top Sellers
| 1 |
HM
HealthCor Management
New York
|
-$22.2M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$12.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.3M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$9.27M |
| 5 |
PA
Perceptive Advisors
New York
|
-$3.06M |
COLL Hedge Fund Activity: Q1 2017 in Review
83 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2017, worth a combined $235M — down 35% from $363M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new COLL positions and 12 closed out — a net gain of 2 holders — while 36 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $22M. The largest seller was HealthCor Management, exiting entirely with an estimated $22.2M sold.
- 83 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2017, down from 88 in Q4 2016.
- Funds reported $235M of Collegium Pharmaceutical stock for Q1 2017, down 35% quarter-over-quarter.
- 14 funds opened new Collegium Pharmaceutical positions in Q1 2017 and 12 closed out, a net change of +2 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2017 was BlackRock, an estimated $22M added.
- The largest Collegium Pharmaceutical seller in Q1 2017 was HealthCor Management, an estimated $22.2M sold.
Based on aggregated 13F filings for Q1 2017.